Sandra Lee Sellam, MS | |
10712 183rd Street Ct E, Puyallup, WA 98374-8909 | |
(206) 639-3816 | |
Not Available |
Full Name | Sandra Lee Sellam |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 10712 183rd Street Ct E, Puyallup, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174148878 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TF0200X | Psychologist - Forensic | (Washington) | Secondary |
101YM0800X | Counselor - Mental Health | MC61062196 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Sandra Lee Sellam, MS 10712 183rd Street Ct E, Puyallup, WA 98374-8909 Ph: (206) 639-3816 | Sandra Lee Sellam, MS 10712 183rd Street Ct E, Puyallup, WA 98374-8909 Ph: (206) 639-3816 |
News Archive
To provide integrated care for people who have diabetes and may be at risk of developing related medical complications, the U.S. health care system needs to continue building effective multidisciplinary care team models, according to new recommendations issued by the Endocrine Society today.
Adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate therapy than hormone therapy alone, according to a new study in the Journal of Clinical Oncology this week from Penn Medicine researchers.
Sigma-Aldrich Corporation today announced it has entered into an exclusive agreement with the Wellcome Trust Sanger Institute to manufacture and distribute the Sanger Institute's arrayed lentiviral CRISPR library. The library will be the first of its kind, providing researchers with a collection of individual clones designed to knock out every known human and mouse protein-coding gene using the CRISPR system.
ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.
› Verified 6 days ago